RPL17 and non-small cell lung carcinoma: In a previous single-arm trial assessing the safety and efficacy of PD - 1 inhibitors in advanced NSCLC, PD - 1 blockade (Camrelizumab)-activated neoantigen-specific cellular therapy (aNASCT) demonstrated safety and immunogenicity in NSCLC patients, suggesting its promising potential in cancer immunotherapy (42).